Literature DB >> 28590545

The utility of a single simple question in the evaluation of patients with myasthenia gravis.

Alon Abraham1, Ari Breiner1, Carolina Barnett1, Hans D Katzberg1, Vera Bril1.   

Abstract

INTRODUCTION: Assessing myasthenia gravis (MG) can be challenging, and multiple scales are available to evaluate disease severity. We evaluated the utility of a single, simple question, as part of the MG evaluation: "What percentage of normal do you feel regarding your MG, 0%-100% normal?"
METHODS: A retrospective chart review of patients attending the neuromuscular clinic from January 2014 to December 2015 was performed. Responses were correlated with symptoms and signs, the Quantitative Myasthenia Gravis Score (QMGS), the Myasthenia Gravis Impairment Index (MGII), and the 15-item Myasthenia Gravis Quality of Life scale (MG-QOL15).
RESULTS: The total cohort included 169 patients. The percentage of normal correlated strongly with limb muscle weakness and MG scales, moderately with bulbar and respiratory symptoms, and weakly with ocular manifestations. DISCUSSION: The question, "What percentage of normal do you feel regarding your MG?" is feasible and valid, and can be incorporated easily into routine clinical evaluation. Muscle Nerve 57: 240-244, 2018.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  MG-QOL15; MGII; QMGS; grip; myasthenia gravis; percentage of normal

Mesh:

Year:  2017        PMID: 28590545     DOI: 10.1002/mus.25720

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  6 in total

1.  Criteria for Treatment Response in Myasthenia Gravis: Comparison Between Absolute Change and Improvement Percentage in Severity Scores.

Authors:  Hong-Yan Li; Ping Jiang; Yanchen Xie; Bing Liang; Ling Li; Cuiping Zhao; Yao-Xian Yue; Hai-Feng Li
Journal:  Front Neurol       Date:  2022-06-02       Impact factor: 4.086

2.  Myasthenia Gravis Impairment Index: Sensitivity for Change in Generalized Muscle Weakness.

Authors:  Robert H P de Meel; Carolina Barnett; Vera Bril; Martijn R Tannemaat; Jan J G M Verschuuren
Journal:  J Neuromuscul Dis       Date:  2020

Review 3.  Expanding the Role of the Pharmacist: Immunoglobulin Therapy and Disease Management in Neuromuscular Disorders.

Authors:  Eric M Tichy; Barbara Prosser; Drew Doyle
Journal:  J Pharm Pract       Date:  2020-07-17

4.  Efficacy and Safety of Tacrolimus Therapy for a Single Chinese Cohort With Very-Late-Onset Myasthenia Gravis.

Authors:  Yiming Zheng; Xiaoqiu Yuan; Caifeng Zhang; Ran Liu; Haiqiang Jin; Hongjun Hao; Fan Li; Yawen Zhao; Yun Yuan; Zhaoxia Wang; Feng Gao
Journal:  Front Neurol       Date:  2022-03-30       Impact factor: 4.003

5.  Usefulness of subcutaneous immunoglobulin therapy in the management of myasthenia gravis: a retrospective cohort study.

Authors:  Marlène Barnay; Fanny Duval; Guilhem Solé; Louis Carla; Stéphane Mathis; Gwendal Le Masson
Journal:  J Neurol       Date:  2022-08-22       Impact factor: 6.682

6.  Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study.

Authors:  Hong-Yan Li; Li-Yuan Shao; Min Song; Shi-Min Hu; Yao-Xian Yue; Hai-Feng Li
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.